ARK 每周股评 – 7/23/2022

我们每周都会与投资者分享我们策略中一周内一天内升值或下跌超过15%的股票的周评。我们希望您觉得这篇评论有用。

We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Farfetch (FTCH)
+15%Shares of Farfetch traded up 15% on Tuesday, participating in a broad-based rally in consumer stocks. Farfetch operates online and physical marketplaces for luxury retail goods internationally, as well as back-end technology solutions for third-party retailers. We believe the company is well-positioned to monetize on luxury retail's shift from brick-and-mortar to e-commerce and e-concession business models.

注:Farfetch的股价周二上涨了15%,参与了消费股的广泛反弹。Farfetch在国际上经营奢侈品零售商品的在线和实体市场,并为第三方零售商提供后端技术解决方案。我们认为,该公司在奢侈品零售业从实体店向电子商务和电子特许经营模式的转变中处于有利地位,可以实现货币化。
Invitae (NVTA)
-17%Shares of Invitae traded down 17% on Tuesday after the company announced a major strategic realignment and corporate restructuring. Invitae’s current COO, Kenneth D. Knight––previously VP at Amazon (AMZN)––will replace Sean George as CEO. Randy Scott, Invitae’s co-founder and former CEO, will take an active role as Chairman of the Board, and co-founder Sean George will remain on the Board.The genetic testing and information company will reduce its workforce and geographic footprint to lower costs and will focus on its most profitable markets and products. Invitae will continue to invest in areas with mature reimbursement schemes where it enjoys a commanding presence and/or differentiated capabilities: oncology, reproductive health, rare disease, and pharmacogenomics. Importantly, the company will continue integrating its robust suite of digital services into its testing menu to create product experiences that, in our view, no other firm can replicate.Although Invitae’s leadership and ARK firmly believe in the viability of genome management as a service, the current market environment and the company’s leveraged balance sheet no longer will accommodate Invitae’s previous broad-based and aggressive investment plans. Over the next year, we believe Invitae will have to demonstrate operational improvements and commercial execution in its new oncology services. If successful, which we believe it will be, Invitae should be able to refinance its 2024 debt on favorable terms. Based on discussions with Invitae’s executives and board members, we believe that the future returns to this strategy far outweigh the risks, especially at its current valuation.

注:Invitae周二股价下跌17%,此前该公司宣布进行重大战略调整和公司重组。Invitae目前的首席运营官Kenneth D. Knight--之前是亚马逊(AMZN)的副总裁--将取代Sean George担任首席执行官。Invitae的联合创始人和前首席执行官Randy Scott将作为董事会主席发挥积极作用,联合创始人Sean George将继续留在董事会中。Invitae将继续投资于具有成熟的报销计划的领域,它在这些领域享有绝对的优势和/或差异化的能力:肿瘤学、生殖健康、罕见病和药物基因组学。重要的是,该公司将继续把其强大的数字服务套件整合到其测试菜单中,以创造我们认为其他公司无法复制的产品体验。尽管Invitae的领导层和ARK坚信基因组管理作为一种服务的可行性,但目前的市场环境和该公司的杠杆资产负债表不再能适应Invitae以前广泛和积极的投资计划。在接下来的一年里,我们相信Invitae将必须证明其新的肿瘤学服务的运营改进和商业执行。如果成功的话(我们相信它将会成功),Invitae应该能够以有利的条件对其2024年的债务进行再融资。根据与Invitae高管和董事会成员的讨论,我们认为这一战略的未来回报远远超过了风险,特别是在其目前的估值下。
Verve Therapeutics (VERV)
+22%Shares of Verve Therapeutics traded up 22% on Tuesday, after the company’s recent announcement that it dosed its first human patient with an investigational in vivo base-editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia. The treatment could offer an alternative for hypercholesterolemia patients who have difficulty managing the side effects of statins and other therapeutic options. Founded by world-renowned experts in cardiovascular medicine, human genetics, and gene editing, Verve Therapeutics develops transformative once-and-done therapies for coronary heart disease.

注:Verve Therapeutics公司的股价在周二上涨了22%,此前该公司最近宣布,它给第一个人类患者注射了一种体内基底编辑药物VERVE-101,作为杂合子家族性高胆固醇血症的潜在疗法。这种治疗方法可以为难以控制他汀类药物和其他治疗方案的副作用的高胆固醇血症患者提供一种选择。Verve Therapeutics公司由心血管医学、人类遗传学和基因编辑方面的世界知名专家创立,为冠心病开发变革性的一次性疗法。
Silvergate Capital (SI)
+16%Shares of Silvergate Capital traded up 22% and 16% on Tuesday and Wednesday, respectively, after the company reported second-quarter earnings that surpassed analyst estimates and the crypto markets began to rally. Notably, during the second quarter, US dollar transfers on the Silvergate Exchange Network (“SEN”) increased 34% sequentially, faster than the 6% growth in the crypto market as defined BTC (bitcoin) and ETH (ether). Founded in the late 1980s as a traditional commercial bank, today Silvergate is focused on providing banking services to companies seeking exposure to cryptoassets.

注:银门资本的股票在周二和周三分别上涨了22%和16%,此前该公司公布的第二季度收益超过了分析师的预期,加密货币市场开始反弹。值得注意的是,在第二季度,银门交易所网络("SEN")上的美元转账连续增长34%,比定义为BTC(比特币)和ETH(以太坊)的加密货币市场6%的增长速度更快。银之门成立于20世纪80年代末,是一家传统的商业银行,今天,银之门专注于为寻求接触加密资产的公司提供银行服务。
Monday.com (MNDY)
+16%Shares of Monday.com traded up 16% on Wednesday, participating in a broad-based rally in software stocks. We maintain long-term conviction in Monday.com's ability to increase market share in the cloud-based productivity and collaboration software space. Monday.com provides cloud-based software applications and work management tools globally.

注:Monday.com的股票在周三交易中上涨了16%,参与了软件股的广泛反弹。我们对Monday.com在基于云的生产力和协作软件领域增加市场份额的能力保持长期的信念。Monday.com在全球提供基于云的软件应用程序和工作管理工具。
Senti Biosciences (SNTI)
+17%Shares of Senti Biosciences traded up 17% on Wednesday, participating in a broad-based rally in genomics stocks. Senti Biosciences uses genetic logic circuit technology to develop highly precise medicines and cell therapy treatments for a broad range of indications.

注:Senti生物科学公司的股票在周三交易中上涨了17%,参与了基因组学股票的广泛反弹。Senti生物科学公司利用基因逻辑电路技术为广泛的适应症开发高度精确的药物和细胞治疗方法。
1Life Healthcare (ONEM)
+68%Shares of 1Life Healthcare (One Medical) traded up 68% Thursday after the company announced that Amazon is acquiring it for $3.9 billion. 1Life Healthcare provides a membership-based, primary care platform with seamless digital health and in-office care.

注:1Life Healthcare(One Medical)的股价周四上涨了68%,此前该公司宣布亚马逊将以39亿美元收购它。1Life Healthcare提供了一个基于会员制的初级保健平台,具有无缝的数字健康和诊室护理。
Velo3D (VLD)
+16%Shares of Velo3D rose 16% on Thursday in response to news of the company’s partnership with Hartech Group to distribute its end-to-end additive manufacturing solutions to the federal government. Velo3D is an additive manufacturing and 3D printing company specializing in support-free powder bed fusion. SpaceX is its largest customer and a strategic investor.

注:Velo3D的股价周四上涨了16%,以回应该公司与Hartech集团合作,向联邦政府分销其端到端增材制造解决方案的消息。Velo3D是一家增材制造和3D打印公司,专门从事无支撑粉末床融合技术。SpaceX是其最大的客户和战略投资者。

主题测试文章,只做测试使用。发布者:star,转转请注明出处:https://wallstreetgm.com/ark-%e6%af%8f%e5%91%a8%e8%82%a1%e8%af%84-7-23-2022/

(0)
上一篇 2022年7月22日 下午2:04
下一篇 2022年7月30日 下午9:23

相关推荐

发表回复

您的电子邮箱地址不会被公开。